Navigation Links
CerviLenz Receives JumpStart Investment
Date:5/15/2008

CLEVELAND, May 15 /PRNewswire/ -- JumpStart Inc., the Northeast Ohio venture development organization that accelerates the growth of innovative early-stage businesses and ideas, has announced an investment commitment of $350,000 in CerviLenz(TM), Inc. The Cleveland-based company is commercializing a patented, Federal Drug Administration cleared medical device that allows obstetricians to easily measure cervical length in pregnant women, which has been established by the National Institutes of Health as an effective predictor of preterm birth risk.

(Logo: http://www.newscom.com/cgi-bin/prnh/20060209/CLJUMPSTARTLOGO )

According to the American College of Obstetricians and Gynecologists, patients at high risk for preterm births have been difficult to identify and have accounted for more than $2 billion in annual healthcare costs.

"Until recently, the causes of preterm birth have been poorly understood with few existing treatment options available," said Kevin Mendelsohn, the JumpStart Entrepreneur-in-Residence who will be working with the company. "But the recent emergence of progesterone as a therapy to substantially reduce the risk of preterm birth has presented a significant opportunity for CerviLenz. Its medical device provides obstetricians and gynecologists a cost effective alternative to screen women for preterm birth risk and determine whether they are suitable candidates for the therapy or to consult with a high-risk pregnancy specialist," Mendelsohn concluded.

CerviLenz is led by Board Chairman Dr. Michael Ross, a Maternal-Fetal Medicine specialist and Chairman of Obstetrics and Gynecology at Harbor-UCLA Medical Center, and Chief Executive Officer Dean Koch, an industry veteran who has spent the past 10 years with Adeza Biomedical, the first firm in the preterm birth arena. Together, Dr. Ross and Mr. Koch bring extensive clinical experie
'/>"/>

SOURCE JumpStart Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. AGA Medical Corporation Receives CE Mark Approval for the AMPLATZER(R) Vascular Plug III
2. Cancer Centers of North Carolina Receives Prestigious Accreditation
3. Fox Chase Cancer Centers Ning Wong receives ASCO Cancer Foundation Career Development Award
4. Masimo Receives FDA Clearance for Noninvasive Total Hemoglobin
5. Haemacure financing receives shareholder consent - Series B Warrants are amended
6. Gladney Center for Adoption Receives Whole Health Grant from Aetna Foundation
7. Novalar Receives FDA Approval for OraVerse(TM)
8. Cynosures Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval
9. U.S. Navy Receives Funding for Further Development of Hemopure(R)
10. UCSF receives funding for building from California stem cell agency
11. USC receives nearly $27 million in funding for new stem cell research facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... NY, April 23, 2014Men whose testosterone falls below normal ... to be overweight and have heart disease and type ... identify testosterone-deficient men for further testing and possible treatment ... Men,s Health , a peer-reviewed publication from Mary Ann ... the Journal of Men,s Health website at ...
(Date:4/23/2014)... of probiotics, antioxidants and other nutritional compounds, more and ... is getting in on the action. But legitimate skepticism ... industry is responding with clinical research to shore up ... Chemical & Engineering News (C&EN), the weekly news ... Bomgardner, a senior editor at C&EN, writes that about ...
(Date:4/23/2014)... a researcher from the Cancer Science Institute of Singapore ... identified the cancer specific stem cell which causes gastric ... new drugs for the treatment of this disease and ... by Dr Chan Shing Leng, Research Assistant Professor at ... cancer-specific variant of a cell surface protein, CD44v8-10, marks ...
(Date:4/23/2014)... Ritalin, may prevent the depletion of self-control, according to ... of the Association for Psychological Science. , Self-control can ... to focus attention on a boring textbook are hard ... for this difficulty: Exerting self-control for a long period ... on subsequent tasks. , "It is as if self-control ...
(Date:4/22/2014)... leaders visited the New Jersey Institute of Technology ... Bloom for the launch of the New Jersey ... a new model for business innovation through the ... and investment. U.S. Senator Cory Booker, Panasonic Corp. ... New Jersey Lieutenant Governor Kim Guadagno, New Jersey ...
Breaking Medicine News(10 mins):Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:ADHD drug may help preserve our self-control resources 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2
... in brain cells may hold clues for Parkinson,s treatment, researchers ... they,ve discovered collections of brain cells that may play a ... in things like playing the piano and driving a car. ... found the cells in the prefrontal cortex and striatum parts ...
... heart patients when ARB added to ACE inhibitor therapy, study ... angiotensin receptor blocker (ARB) drug to help control blood pressure ... are taking an ACE inhibitor, a new study finds. , ... therapy seems no better than ACE inhibitor therapy alone and ...
... Neurologists at the University at Buffalo are beginning ... on the cause of multiple sclerosis (MS). The researchers ... result from narrowing of the primary veins outside the ... CCSVI. CCSVI is a complex vascular condition ...
... Sexual trauma also associated with women,s urinary tract symptoms, ... -- Psychiatric disorders and sexual trauma in women increase ... as incontinence and overactive bladder, a new study finds. ... -- the Urogenital Distress Inventory-6 and Incontinence Impact Questionnaire-7 ...
... antidepressants for depression never get relief. Why? Because ... to treat it aim at the wrong target, according to ... The medications are like arrows shot at the outer rings ... A study from the laboratory of long-time depression researcher Eva ...
... researchers find , FRIDAY, Oct. 23 (HealthDay News) -- A ... seven-day course in reducing pain after children have their tonsils ... in the October issue of the Archives of Otolaryngology ... tonsillectomy can make children reluctant to eat and drink, leading ...
Cached Medicine News:Health News:Adding Drug Doesn't Help Control Blood Pressure 2Health News:Buffalo neurologists investigate possible new underlying cause of MS 2Health News:Buffalo neurologists investigate possible new underlying cause of MS 3Health News:Buffalo neurologists investigate possible new underlying cause of MS 4Health News:Bladder Problems May Often Be Related to Mental Health 2Health News:Why antidepressants don't work for so many 2Health News:Why antidepressants don't work for so many 3Health News:After Tonsillectomy, Short-Term Antibiotics Effective: Study 2
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... patent application concerning composition of matter, biological targets, mechanism ... cell death.  This patent application describes ... RNA molecules (VSRNAs) which interfere with the basic homeostatic ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: PharmaPoint: ... Market Analysis to 2022 ... - India Drug Forecast and Market Analysis ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... N.J., Nov. 3 , Third-Quarter 2009 Highlights: , ... $0.58 in third-quarter 2008 Record diluted EPS, excluding $0.06 ... $0.75, up 19.0 percent from $0.63 in third-quarter 2008 ... Specialty pharmacy revenues increased 19.2 percent to a record of ...
... , MOUNTAIN VIEW, Calif., Nov. 3 VIVUS, ... promotion of Peter Tam to president of VIVUS. In ... responsibility for VIVUS, development and business functions, including corporate ... regulatory affairs and chemistry, manufacturing and controls. Leland Wilson, ...
Cached Medicine Technology:Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 2Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 3Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 4Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 5Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 6Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 7Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 8Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 9Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 10Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 11Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 12Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 13Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 14Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 15Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 16Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 17Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 18Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 19Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 20Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 21Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 22Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 23Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 24Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 25Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 26Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 27Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 28Medco Delivers Record Third-Quarter 2009 GAAP Diluted EPS of $0.69; Diluted EPS Excluding Amortization of Intangible Assets of $0.75 29VIVUS Announces Promotion of Peter Tam to President 2VIVUS Announces Promotion of Peter Tam to President 3
... better. How can one of the leading ... becoming more convenient to use in all ... TwinFix Suture Anchor with Needles combines the ... and timesaving anchor inserter and needle delivery ...
... The TACIT Threaded Anchor ... used in craniofacial and ... easy, secure tissue reattachment ... suspension. The small size ...
The Mini Anchor is an exceptionally strong, versatile anchor. This anchor comes in either a load-your-own or QUICKANCHOR format, preloaded on either 2/0 or 0 ETHIBOND EXCEL suture with swaged needles...
... FASTIN RC is a ... for rotator cuff procedures. The ... a small core to optimize ... independent suture channels to prevent ...
Medicine Products: